ALGEN Fundamental Analysis - GENOWAY SA

Fundamental Rating

Taking everything into account, ALGEN scores 6 out of 10 in our fundamental rating. ALGEN was compared to 73 industry peers in the Biotechnology industry. While ALGEN belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. ALGEN is not valued too expensively and it also shows a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALGEN had positive earnings in the past year.

In the past year ALGEN had a positive cash flow from operations.

The reported net income has been mixed in the past 5 years: ALGEN reported negative net income in multiple years.

The reported operating cash flow has been mixed in the past 5 years: ALGEN reported negative operating cash flow in multiple years.

1.2 Ratios

ALGEN has a Return On Assets of 3.96%. This is amongst the best in the industry. ALGEN outperforms 80.82% of its industry peers.

With an excellent Return On Equity value of 7.06%, ALGEN belongs to the best of the industry, outperforming 82.19% of the companies in the same industry.

ALGEN's Return On Invested Capital of 6.13% is amongst the best of the industry. ALGEN outperforms 84.93% of its industry peers.

The Average Return On Invested Capital over the past 3 years for ALGEN is significantly below the industry average of 14.37%.

The last Return On Invested Capital (6.13%) for ALGEN is above the 3 year average (5.56%), which is a sign of increasing profitability.

		Industry Rank	Sector Rank
ROA	3.96%
ROE	7.06%
ROIC	6.13%

ROA(3y)4.35%

ROA(5y)1.91%

ROE(3y)7.98%

ROE(5y)2.79%

ROIC(3y)5.56%

ROIC(5y)N/A

1.3 Margins

The Profit Margin of ALGEN (5.86%) is better than 80.82% of its industry peers.

The Operating Margin of ALGEN (8.09%) is better than 80.82% of its industry peers.

Looking at the Gross Margin, with a value of 92.34%, ALGEN belongs to the top of the industry, outperforming 87.67% of the companies in the same industry.

ALGEN's Gross Margin has been stable in the last couple of years.

		Industry Rank	Sector Rank
OM	8.09%
PM (TTM)	5.86%
GM	92.34%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.73%

GM growth 5Y0.4%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.

Compared to 1 year ago, ALGEN has less shares outstanding

Compared to 5 years ago, ALGEN has more shares outstanding

ALGEN has a better debt/assets ratio than last year.

2.2 Solvency

ALGEN has an Altman-Z score of 2.39. This is not the best score and indicates that ALGEN is in the grey zone with still only limited risk for bankruptcy at the moment.

ALGEN has a Altman-Z score of 2.39. This is in the better half of the industry: ALGEN outperforms 68.49% of its industry peers.

ALGEN has a debt to FCF ratio of 1.41. This is a very positive value and a sign of high solvency as it would only need 1.41 years to pay back of all of its debts.

The Debt to FCF ratio of ALGEN (1.41) is better than 91.78% of its industry peers.

A Debt/Equity ratio of 0.26 indicates that ALGEN is not too dependend on debt financing.

The Debt to Equity ratio of ALGEN (0.26) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.26
Debt/FCF	1.41
Altman-Z	2.39

ROIC/WACC0.87

WACC7.07%

2.3 Liquidity

A Current Ratio of 1.92 indicates that ALGEN should not have too much problems paying its short term obligations.

Looking at the Current ratio, with a value of 1.92, ALGEN is in line with its industry, outperforming 47.95% of the companies in the same industry.

A Quick Ratio of 1.81 indicates that ALGEN should not have too much problems paying its short term obligations.

With a Quick ratio value of 1.81, ALGEN perfoms like the industry average, outperforming 54.79% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.92
Quick Ratio	1.81

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.41%, which is quite good.

Looking at the last year, ALGEN shows a quite strong growth in Revenue. The Revenue has grown by 10.04% in the last year.

ALGEN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.46% yearly.

EPS 1Y (TTM)18.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%108%

Revenue 1Y (TTM)10.04%

Revenue growth 3Y16.31%

Revenue growth 5Y18.46%

Sales Q2Q%5.92%

3.2 Future

The Earnings Per Share is expected to decrease by 0.00% on average over the next years.

ALGEN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.37% yearly.

EPS Next Y-100%

EPS Next 2Y-41.42%

EPS Next 3Y0%

EPS Next 5YN/A

Revenue Next Year-7.14%

Revenue Next 2Y3.51%

Revenue Next 3Y10.37%

Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 13.43, ALGEN is valued correctly.

Based on the Price/Earnings ratio, ALGEN is valued cheaper than 89.04% of the companies in the same industry.

ALGEN is valuated cheaply when we compare the Price/Earnings ratio to 27.90, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	13.43
Fwd PE	N/A

4.2 Price Multiples

ALGEN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ALGEN is cheaper than 91.78% of the companies in the same industry.

Based on the Price/Free Cash Flow ratio, ALGEN is valued cheaply inside the industry as 93.15% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	5.9
EV/EBITDA	4.67

4.3 Compensation for Growth

ALGEN has a very decent profitability rating, which may justify a higher PE ratio.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-41.42%

EPS Next 3Y0%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALGEN!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GENOWAY SA

EPA:ALGEN (10/6/2025, 7:00:00 PM)

2.82

-0.06 (-2.08%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners5.68%

Inst Owner ChangeN/A

Ins Owners10.39%

Ins Owner ChangeN/A

Market Cap26.73M

Analysts86.67

Price Target6.02 (113.48%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	13.43
Fwd PE	N/A
P/S	1.25
P/FCF	5.9
P/OCF	3.87
P/B	1.5
P/tB	2.2
EV/EBITDA	4.67

EPS(TTM)0.21

EY7.45%

EPS(NY)0

Fwd EYN/A

FCF(TTM)0.48

FCFY16.95%

OCF(TTM)0.73

OCFY25.84%

SpS2.26

BVpS1.88

TBVpS1.28

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	3.96%
ROE	7.06%
ROCE	7.62%
ROIC	6.13%
ROICexc	7.79%
ROICexgc	11.35%
OM	8.09%
PM (TTM)	5.86%
GM	92.34%
FCFM	21.15%

ROA(3y)4.35%

ROA(5y)1.91%

ROE(3y)7.98%

ROE(5y)2.79%

ROIC(3y)5.56%

ROIC(5y)N/A

ROICexc(3y)6.94%

ROICexc(5y)N/A

ROICexgc(3y)9.99%

ROICexgc(5y)N/A

ROCE(3y)6.91%

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.73%

GM growth 5Y0.4%

F-Score5

Asset Turnover0.68

Health

		Industry Rank	Sector Rank
Debt/Equity	0.26
Debt/FCF	1.41
Debt/EBITDA	0.77
Cap/Depr	55.06%
Cap/Sales	11.1%
Interest Coverage	250
Cash Conversion	114.18%
Profit Quality	360.76%
Current Ratio	1.92
Quick Ratio	1.81
Altman-Z	2.39

F-Score5

WACC7.07%

ROIC/WACC0.87

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)18.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%108%

EPS Next Y-100%

EPS Next 2Y-41.42%

EPS Next 3Y0%

EPS Next 5YN/A

Revenue 1Y (TTM)10.04%

Revenue growth 3Y16.31%

Revenue growth 5Y18.46%

Sales Q2Q%5.92%

Revenue Next Year-7.14%

Revenue Next 2Y3.51%

Revenue Next 3Y10.37%

Revenue Next 5YN/A

EBIT growth 1Y0.64%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year200%

EBIT Next 3Y68.69%

EBIT Next 5YN/A

FCF growth 1Y308.02%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y1010.09%

OCF growth 3YN/A

OCF growth 5YN/A

GENOWAY SA (ALGEN.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens